BCR-ABL, breakpoint cluster region–Abelson murine leukemia viral oncogene homolog 1, is an abnormal protein mostly found in chronic myelogenous leukemia (CML) due to the fusion of abnormal configuration of DNA where the abl gene is fused to the BCR gene (The Philadelphia chromosome); BCR-ABL and its mutants can promote and maintain the malignant behavior of the cancer cells. The identification of BCR-ABL as a driver gene has led to the rapid development of anticancer therapeutics agents, including Imatinib, Dasatinib, Ponatinib and Nilotinib.
Ba/F3 cell, a murine interleukin-3 dependent pro-B cell line, is a popular system for exploring both kinases and their inhibitors, because some protein kinases can render the Ba/F3 cells to be depended on the activation of the kinases instead of IL-3 supplement, while their inhibitors can antagonize the kinase-dependent growth effects.